- Prescriptions
- Generic Prescriptions
Depot medroxyprogesterone acetate injection is a contraceptive injection. It is similar to the hormone called progesterone, which is produced in the body by the ovaries. The contraceptive injection mainly works by stopping the ovaries from releasing an egg (ovulation). The contraceptive injections are much more effective than oral one. Their effectiveness ranges from 94% to 99%. These injections are taken after every twelve week time period. However, lack of resources such as trained nurses or healthcare professionals and infrastructure to administer injectable contraceptives in several developing and underdeveloped countries may hinder the growth of the market over forecast period. Also, availability of alternative contraceptive methods such as condoms, IUCDs, oral contraceptives may also restrain the market growth.
Depot Medroxyprogesterone Acetate Injection Market Key Developments
- The Pfizer Inc., collaborated with the Bill & Melinda Gates Foundation, and the Children's Investment Fund Foundation (CIFF) to broaden the access to Pfizer's all-in-one injectable contraceptive Sayana Press which will be available to qualified purchasers at a guaranteed price of US $0.85 per dose, to help the females in poor countries.
Depot Medroxyprogesterone Acetate Injection Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
x%
Largest Market
North-America
Fastest Growing Market
Asia-Pacific
Depot Medroxyprogesterone Acetate Injection Market Dynamics
The factors which are streaming the growth of this market are growing awareness among urban young woman, who are intended postpone pregnancy, increase in disposable income in developing countries and growing middle class population in emerging countries, and increasing collaboration between public, private, and non-governmental organization effectively helping to improve the access to medication in resource constrained and underdeveloped countries.
North-America Got Significant Share
Depot Medroxyprogesterone Acetate Injection Market Regional Analysis
North America dominates the global depot medroxyprogesterone acetate injection market followed by Europe. However, Asia Pacific and Africa markets are projected to grow with a high CAGR owing to increase in awareness about the advanced methods of contraception and active involvement of government and NGO agencies to promote advanced methods of contraception.
Latin America
Europe
Asia Pacific
Middle East
North America
Key Features of the Reports
- The depot medroxyprogesterone acetate injection market report provides granular level information about the market size, regional market share, historic market (2018-2022) and forecast (2023-2029)
- The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments and startup's details that are actively working in the market
- The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario
- The report analyses the impact of socio-political environment through PESTLE Analysis and competition through Porter's Five Force Analysis in addition to recent technology advancements and innovations in the market
Depot Medroxyprogesterone Acetate Injection Market Segmentation
By Type
By End User
- Hospital
- Pharmacy
- Others
By Geography
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Frequently Asked Questions
The depot medroxyprogesterone acetate injection market key players are: Pfizer Inc., Fangtong Pharma.Co. Ltd, Gador S.A., Sigma-Aldrich Co. LLC., Teva Pharmaceutical Industries Ltd., Greenstone LLC, Serum Internation Ltd., West-Coast Pharmaceutical, Arrow Pharma Group,, Zuche Pharmaceuticals Pvt. Ltd.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
| 1.Executive Summary |
| 2.Global Depot Medroxyprogesterone Acetate Injection Market Introduction |
| 2.1.Global Depot Medroxyprogesterone Acetate Injection Market - Taxonomy |
| 2.2.Global Depot Medroxyprogesterone Acetate Injection Market - Definitions |
| 2.2.1.Type |
| 2.2.2.End User |
| 2.2.3.Region |
| 3.Global Depot Medroxyprogesterone Acetate Injection Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Product Landscape |
| 3.6. New Product Launches |
| 3.7. Impact of COVID 19 on Market |
| 4.Global Depot Medroxyprogesterone Acetate Injection Market Analysis, 2018-2022 and Forecast 2023-2029 |
| 4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5.Global Depot Medroxyprogesterone Acetate Injection Market By Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 5.1. Prescriptions |
| 5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Generic Prescriptions |
| 5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 6.Global Depot Medroxyprogesterone Acetate Injection Market By End User, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 6.1. Hospital |
| 6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Pharmacy |
| 6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Others |
| 6.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 6.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7.Global Depot Medroxyprogesterone Acetate Injection Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Europe |
| 7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia Pacific (APAC) |
| 7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Middle East and Africa (MEA) |
| 7.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Latin America |
| 7.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million) |
| 7.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.5.3. Market Opportunity Analysis |
| 8.North America Depot Medroxyprogesterone Acetate Injection Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 8.1. Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1.Prescriptions |
| 8.1.2.Generic Prescriptions |
| 8.2. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1.Hospital |
| 8.2.2.Pharmacy |
| 8.2.3.Others |
| 8.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 8.3.1.United States of America (USA) |
| 8.3.2.Canada |
| 9.Europe Depot Medroxyprogesterone Acetate Injection Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 9.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1.Prescriptions |
| 9.1.2.Generic Prescriptions |
| 9.2. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1.Hospital |
| 9.2.2.Pharmacy |
| 9.2.3.Others |
| 9.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 9.3.1.Germany |
| 9.3.2.France |
| 9.3.3.Italy |
| 9.3.4.United Kingdom (UK) |
| 9.3.5.Spain |
| 9.3.6.Rest of EU |
| 10.Asia Pacific (APAC) Depot Medroxyprogesterone Acetate Injection Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 10.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1.Prescriptions |
| 10.1.2.Generic Prescriptions |
| 10.2. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1.Hospital |
| 10.2.2.Pharmacy |
| 10.2.3.Others |
| 10.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 10.3.1.China |
| 10.3.2.India |
| 10.3.3.Australia and New Zealand (ANZ) |
| 10.3.4.Japan |
| 10.3.5.Rest of APAC |
| 11.Middle East and Africa (MEA) Depot Medroxyprogesterone Acetate Injection Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 11.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1.Prescriptions |
| 11.1.2.Generic Prescriptions |
| 11.2. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1.Hospital |
| 11.2.2.Pharmacy |
| 11.2.3.Others |
| 11.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 11.3.1.GCC Countries |
| 11.3.2.South Africa |
| 11.3.3.Rest of MEA |
| 12.Latin America Depot Medroxyprogesterone Acetate Injection Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million) |
| 12.1. Type Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1.Prescriptions |
| 12.1.2.Generic Prescriptions |
| 12.2. End User Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.2.1.Hospital |
| 12.2.2.Pharmacy |
| 12.2.3.Others |
| 12.3. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%) |
| 12.3.1.Brazil |
| 12.3.2.Mexico |
| 12.3.3.Rest of LA |
| 13. Competition Landscape |
| 13.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis) |
| 13.2.1.Pfizer Inc. |
| 13.2.2.Fangtong Pharma.Co. Ltd |
| 13.2.3.Gador S.A. |
| 13.2.4.Sigma-Aldrich Co. LLC. |
| 13.2.5.Teva Pharmaceutical Industries Ltd. |
| 13.2.6.Greenstone LLC |
| 13.2.7.Serum Internation Ltd. |
| 13.2.8.West-Coast Pharmaceutical |
| 13.2.9.Arrow Pharma Group, |
| 13.2.10.Zuche Pharmaceuticals Pvt. Ltd. |
| 14. Research Methodology |
| 15. Appendix and Abbreviations |
- Pfizer Inc.
- Fangtong Pharma.Co. Ltd
- Gador S.A.
- Sigma-Aldrich Co. LLC.
- Teva Pharmaceutical Industries Ltd.
- Greenstone LLC
- Serum Internation Ltd.
- West-Coast Pharmaceutical
- Arrow Pharma Group,
- Zuche Pharmaceuticals Pvt. Ltd.